What is Soligenix?
Soligenix is a clinical-stage biopharmaceutical firm dedicated to developing novel therapeutics for inflammatory conditions with unmet medical needs. The company is also actively engaged in creating biodefense vaccines and treatments, positioning itself at the intersection of public health and advanced medical science. Its strategic focus on critical health challenges aims to leverage its scientific pipeline for substantial market impact.
How much funding has Soligenix raised?
Soligenix has raised a total of $35M across 4 funding rounds:
Stock Offering
$7.1M
Debt
$350K
Debt
$20M
Stock/Share Issuance
$7.5M
Stock Issuance/Offering (2013): $7.1M, investors not publicly disclosed
Debt (2020): $350K led by PPP
Debt (2020): $20M supported by Pontifax Medison Debt Financing
Stock/Share Issuance (2025): $7.5M, investors not publicly disclosed
Key Investors in Soligenix
Pontifax Medison Debt Financing
Pontifax Medison Debt Financing is likely a specialized debt financing provider focused on the healthcare and life sciences sectors, offering capital solutions to companies like Soligenix.
PPP
Public-Private Partnership
What's next for Soligenix?
The recent major strategic investment signals a pivotal phase for Soligenix, likely enabling the acceleration of its clinical trial programs and the expansion of its biodefense initiatives. This infusion of capital is expected to support the progression of its lead candidates through regulatory pathways and potentially broaden its research and development capabilities. The company's trajectory suggests a continued emphasis on innovation and strategic partnerships to capitalize on its therapeutic and biodefense platforms.
See full Soligenix company page
